BII lands major funding boost for European biosolutions
BioInnovation Institute (BII), a Danish innovation hub focused on life science and biosolutions, has secured a new €25 million funding commitment from the Novo Nordisk Foundation. The capital will be deployed to support early-stage European startups developing biological solutions to address challenges in health, climate, and sustainable production.
Targeting early-stage European biosolutions startups
The fresh funding will strengthen BII‘s ability to back founders at the pre-seed and seed stages, a critical gap in the European deep tech and life sciences funding landscape. The institute typically supports startups through a mix of non-dilutive grants, equity investments, and structured accelerator-style programs that provide lab facilities, mentorship, and business development support.
By focusing on biosolutions – technologies that use biological systems, organisms, or processes – BII aims to accelerate innovations such as precision fermentation, bio-based materials, advanced therapeutics, and sustainable agriculture. These areas are increasingly seen as key to meeting EU climate targets and strengthening the region’s strategic autonomy in health and food systems.
Novo Nordisk Foundation doubles down on life science innovation
The Novo Nordisk Foundation, one of the world’s largest philanthropic foundations, has been steadily expanding its role as a cornerstone backer of Nordic and European life science innovation. Its renewed commitment to BII underscores a long-term strategy to translate cutting-edge research into scalable companies capable of global impact.
With the new €25 million, BII is expected to increase the number of startups it can onboard annually, broaden its pan-European reach, and deepen collaboration with universities, research hospitals, and industrial partners. The move is likely to attract additional venture capital into the sector, as institutional investors increasingly look to de-risk early-stage opportunities through partnerships with specialized innovation hubs.
Strengthening Europe’s biosolutions ecosystem
Industry observers note that the funding comes at a pivotal moment, as European founders in synthetic biology, biomanufacturing, and climate tech seek capital-intensive lab infrastructure and patient investors. By combining financial backing with technical and regulatory expertise, BII and the Novo Nordisk Foundation aim to turn promising research into commercially viable ventures that can scale globally while anchoring jobs and intellectual property in Europe.